Atty Docket No. 17682A-005100US

PTO FAX NO.:

703/308-6916

ATTENTION:

MR. GILLON

FAX RECEIVED

DEC 0 4 2002

PETITIONS OFFICE

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER Owens

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s) in re Application of Charles R. Petrie et al., Application No. 09/693,213, filed October 19, 2000 for CROSS-LINKING OLIGONUCLEOTIDES is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

 Supplement to Petition Under 37 CFR 1.47 (2 pgs.) with copy of 11/19/02 letter to inventor Hurst and copy of returned FedEx package (2 pgs.)

Number of pages being transmitted, including this page: 6

Dated: December 4, 2002

Mile Mewell

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 415-576-0200

Fax: 415-576-0300

SF 1410786 vl

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 703-308-6916 on 34302

Docket No.: 17682A-005100US Client Ref. No.: 116E

TOWNSEND and TOWNSEND and CREW LLP

Mill Murl

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Owens

Charles R. Petrie et al.

Art Unit:

1623

Application No.: 09/693,213

SUPPLEMENT TO PETITION UNDER 37

C.F.R. 1.47

Filed: October 19, 2000

For: CROSS-LINKING **OLIGONUCLEOTIDES**

FAX RECEIVED

DEC 0 4 2002

PETITIONIS OFFICE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to the petition under 37 C.F.R. 1.47(a) filed November 27, 2002, Applicant hereby submits copies of the letter that was sent to the inventor on November 19, 2002 by Federal Express and a copy of the front of the envelope, which was retuned to us after three attempts at delivery.

This letter was sent to the inventor, Gerald D. Hurst, at his last known address, 39 Painted Sunset, The Woodlands, Texas 77380.

Applicant submits that the co-inventor, Gerald Hurst, cannot be reached after diligent efforts have been made, and requests that the petition filed November 27, 2002 be granted and this application be filed and prosecuted on behalf of the joint inventors pursuant to 37 C.F.R. 1.47 (a).

PATENT

Charles R. Petrie et al. Application No.: 09/693,213 Page 2

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned.

Respectfully submitted,

Joel G. Ackerman Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300

JA:ja

SF 1411395 v1

TOWNSEND and TOWNSEND and CREW

Palo Alto, California Tel 650 326-2400

Denver, Colorado Tel 303 571-4000

Walnut Creck, California Tel 925 472-5000

Seattle, Washington Tel 206 467-9600 San Francisco

Two Embarcadero Center 8th Floor San Francisco California 94111-3834 Tel 415 576-0200 Fax 415 576-0300

November 19, 2002

VIA FEDEX

Gerald D. Hurst 39 Painted Sunset The Woodlands, TX 77380

Re:

US Patent Application No. 09/693,213

For: CROSS-LINKING OLIGONUCLEOTIDES

Filed: October 19, 2000 Epoch Reference No.: 116E Our File No.: 17682A-005100US FAX RECEIVED

DEC 0 4 2002

PETITIONIC CERTICE

Dear Dr. Hurst:

At Epoch's request, we filed an application for reissue of U.S. patent 5,824,796, of which you are named as an inventor.

To complete the documentation, your signature is needed on the reissue declaration. Enclosed is a copy of the complete application as filed, together with the necessary declaration. If it is satisfactory, please sign, date and return it to me in the enclosed Federal Express envelope by next Tuesday, November 26.

If you have any questions about this application or the declaration, please call me at the above number.

Thank you very much for your assistance.

Very truly yours,

Joel G. Ackerman Of Counsel

JGA:nn Enclosures SF 1407578 v1

